Over the last three decades antibody therapies have been developed against a host of diseases including autoimmune disorders, infectious diseases, and cancer. Traditional technologies, however, have had limited success in delivering antibodies for difficult but highly promising targets, such as GPCRs and ion channels.
In this webinar hosted by GEN, panelists from Genovac, present case studies of how they we overcome these antibody discovery and development challenges by leveraging Genovac's core genetic immunization technology and the Beacon optofluidic system to rapidly discover antibodies against challenging targets, such as GPCRs, from a variety of different animal species.
To play the webcast register here.
If you would you like to discuss this research piece get in touch